nach oben

Erschienen in:

01.03.2023 | Review

Hair loss during and after breast cancer therapy

verfasst von: Lucy Rose, Maryam Lustberg, Kathryn J. Ruddy, Elizabeth Cathcart-Rake, Charles Loprinzi, Brittany Dulmage

Erschienen in: Supportive Care in Cancer | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

For patients diagnosed with breast cancer, alopecia can be a distressing side effect of treatment. Major surgeries, cytotoxic chemotherapy, and endocrine therapy may result in several different types of alopecia. This article reviews the underlying mechanisms, etiology, prevention strategies, and treatment options for chemotherapy-induced alopecia, telogen effluvium, and endocrine-induced alopecia. Here, we aim to provide breast oncologists with a review of the types of hair loss related to cancer therapy and current preventative and treatment options to facilitate informative patient counseling.

Martinez A, Shapiro J, Goldfarb S, Nangia J, Jiminez J, Paus R, Lacoutoure M (2019) CME Part 1: Hair disorders in cancer patients. J Am Acad Dermatol 80(5):1179–1196. https://doi.org/10.1016/j.jaad.2018.03.055CrossRef

Treub R (2010) Chemotherapy induced hair loss. Skin Ther Lett 15(7):5–7

Saggar V et al (2013) Alopecia with endocrine therapies in patients with cancer. Oncologist 18(10):1126–1134CrossRefPubMedPubMedCentral

Hackbarth M, Haas N, Fotopoulou C, Lichtenegger W, Sehouli J (2008) Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women’s cancers. Results of a prospective study. Support Care Cancer 3:267–273CrossRef

Moscetti et al (2015) Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment? Tumori 101(5):469–473CrossRefPubMed

Alonso L, Fuchs E (2006) The hair cycle. J Cell Sci 119:391–393CrossRefPubMed

Stoehr JR, Kosche C, Choi JN (2020) Permanent chemotherapy-induced alopecia: awareness and attitudes among health care providers. Support Care Cancer 28(6):2887–2890CrossRefPubMed

Kang D, Kim I, Choi E et al (2019) Permanent chemotherapy-induced alopecia in patients with breast cancer: a 3-year prospective cohort study. Oncologist 24(3):414–420CrossRefPubMed

Paus R, Haslam IS, Sharov AA, Botchkarev VA (2013) Pathobiology of chemotherapy-induced hair loss. Lancet Oncol 14(2):e50–e59. https://doi.org/10.1016/S1470-2045(12)70553-3CrossRefPubMed

10.

Palamaras I, Misciali C, Vincenzi C, Robles WS, Tosti A (2011) Permanent chemotherapy-induced alopecia: a review. J Am Acad Dermatol 64(3):604–606. https://doi.org/10.1016/j.jaad.2010.03.020CrossRefPubMed

11.

Tran D, Sinclair RD, Schwarer AP, Chow CW (2000) Permanent alopecia following chemotherapy and bone marrow transplantation. Australas J Dermatol 41(2):106–108. https://doi.org/10.1046/j.1440-0960.2000.00405.xCrossRefPubMed

12.

Basilio FM, Brenner FM, Werner B, Rastelli GJ (2015) Clinical and histological study of permanent alopecia after bone marrow transplantation. An Bras Dermatol 90(6):814–821. https://doi.org/10.1590/abd1806-4841.20154013CrossRefPubMedPubMedCentral

13.

E Cathcart-Rake, CL Loprinzi, F Couch, J Olson, B Dulmage, M Lustberg, N Larson, KJ Ruddy (2022) Eyebrow/eyelash loss among survivors [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7–10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res, 82(4 Suppl):Abstract nr P4–10–11

14.

Wantanabe T et al (2019) A multicenter survey of temporal changes in chemotherapy-induced hair loss in breast cancer patients. PLoS ONE. https://doi.org/10.1371/journal.pone.0208118CrossRef

15.

The Science of Scalp Cooling. Paxman Scalp Cooling. https://paxmanscalpcooling.com/research/the-science/. Accessed 15 Aug 2022

16.

Cold Caps and Scalp Cooling Systems. https://www.breastcancer.org/treatment-side-effects/hair-loss/cold-caps-scalp-cooling. Accessed 15 Aug 2022

17.

Grevelman E, Breed W (2005) Prevention of chemotherapy-induced hair loss by scalp cooling. Ann Oncol 16(3):352–358. https://doi.org/10.1093/annonc/mdi088CrossRefPubMed

18.

Van den Hurk J, Peerbooms M, van de Poll-Franse L, Nortier J, Coebergh J, Breed W (2012) Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - results of the Dutch Scalp Cooling Registry. Acta Oncol 51(4):497–504. https://doi.org/10.3109/0284186X.2012.658966CrossRefPubMed

19.

Cigler T, Isseroff D, Fiederlein B, Schneider S, Chuang E, Vahdat L, Moore A (2015) Efficacy of scalp cooling in preventing chemotherapy-induced alopecia in breast cancer patients receiving adjuvant docetaxel and cyclophosphamide chemotherapy. Clin Breast Cancer 5:332–334. https://doi.org/10.1016/j.clbc.2015.01.003CrossRef

20.

A Degree of Control: A Guide to Scalp Cooling. Paxman US Incorporated. https://www.stlukes-stl.com/services/womens-services/documents/paxman-scalp-cooling-system.pdf. Accessed 15 Aug 2022

21.

Dilawari A, Gallagher C, Alintah P, Chitalia A, Tiwari S, Paxman R, Adams-Campbell L, Dash C (2021) Does scalp cooling have the same efficacy in black patients receiving chemotherapy for breast cancer? Oncologist 26(4):292-e548. https://doi.org/10.1002/onco.13690CrossRefPubMedPubMedCentral

22.

Araoye E, Stearns V, Aguh C (2020) Considerations for the use of scalp cooling devices in black patients. J Clin Oncol 38(30):3575–3576. https://doi.org/10.1200/JCO.20.02130CrossRefPubMedPubMedCentral

23.

Shorter K, Farjo NP, Picksley SM, Randall VA (2008) Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. Faseb J 22(6):1725–1736. https://doi.org/10.1096/fj.07-099424CrossRefPubMed

24.

Suchonwanit P, Thammarucha S, Leerunyaku K (2019) Minoxidil and its use in hair disorders: a review. Drug Des Dev Theory 13:2777–2786. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691938/CrossRef

25.

Duvic M, Lemak NA, Valero V et al (1996) A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol 35(1):74–78CrossRefPubMed

26.

Prevezas C, Matard B, Pinquier L, Reygagne P (2009) Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer. Br J Dermatol 160(4):883–885CrossRefPubMed

27.

Lyakhovitsky A, Segal O, Maly A, Zlotogorski A, Barzilai A (2022) Permanent chemotherapy-induced alopecia after hematopoietic stem cell transplant treated with low-dose minoxidil. JAAD Case Rep 22:64–67. https://pubmed.ncbi.nlm.nih.gov/35321258/CrossRefPubMedPubMedCentral

28.

Rossi A, Caro G, Fortuna MC, Pigliacelli F, D’Arino A, Carlesimo M (2020) Prevention and Treatment of Chemotherapy-Induced Alopecia. Dermatol Pract Concept 10(3):e2020074. https://doi.org/10.5826/dpc.1003a74CrossRefPubMedPubMedCentral

29.

Malkud S (2015) Telogen effluvium: a review. J Clin Diagn Res 9(9):WE01-3. https://doi.org/10.7860/JCDR/2015/15219.6492

30.

Rebora A (2019) Telogen effluvium: a comprehensive review. Clin Cosmet Investig Dermatol 12:583–590. https://doi.org/10.2147/CCID.S200471

31.

Chien Yin GO, Siong-See JL, Wang ECE (2021) Telogen effluvium – a review of the science and current obstacles. J Dermatol Sci 101(3):156–163CrossRefPubMed

32.

Freites-Martinez A, Shapiro J, van den Hurk C et al (2019) Hair disorders in cancer survivors. J Am Acad Dermatol 80(5):1199–1213CrossRefPubMed

33.

Freites-Martinez A et al (2018) Endocrine therapy-induced alopecia in patients with breast cancer. JAMA Dermatol 154(6):670–675CrossRefPubMedPubMedCentral

34.

Saggar V, Shenhong Wu, Dickler MN, Lacouture ME (2013) Alopecia with endocrine therapies in patients with cancer. Oncologist 18(10):1126–1134CrossRefPubMedPubMedCentral

35.

Bhargava S (2014) Increased DHT levels in androgenic alopecia have been selected for to protect men from prostate cancer. Med Hypotheses 82:428–432. https://doi.org/10.1016/j.mehy.2014.01.016CrossRefPubMed

36.

Freites-Martinez A, Shapiro J, Goldfarb S et al (2019) Hair disorders in patients with cancer. J Am Acad Dermatol 80(5):1179–1196CrossRefPubMed

37.

Gallicchio L, Calhoun C, Helzlsouer K (2017) Hair loss associated with aromatase inhibitor treatment among breast cancer patients. J Clin Oncol. https://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.e21619

38.

Al-Niaimi F, Lyon C (2011) Tamoxifen-induced hirsutism. J Drugs Dermatol 10:799–801PubMed

39.

Moscetti L, Agnese Fabbri M, Sperduti I, Fabrizio N et al (2015) Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment? Tumori 101:469–473CrossRefPubMed

40.

Marra A, Curigliano G (2019) Are all cyclin-dependent kinases 4/6 inhibitors created equal? NPJ Breast Cancer 5:27. https://doi.org/10.1038/s41523-019-0121-yCrossRefPubMedPubMedCentral

41.

Eiger D, Wagner M, Pondé NF, Nogueira MS, Buisseret L, de Azambuja E (2020) The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC). Acta Oncol 59(6):723–725. https://doi.org/10.1080/0284186X.2020.1738547CrossRefPubMed

42.

Chan D, Martinez ADF, Goldfarb SB, Modi S, Gajria D, Lacouture ME (2019) CDK4/6 plus aromatase inhibitor-induced alopecia in breast cancer patients. J Clin Oncol 37:15_suppl (e12537-e12537)CrossRef

43.

Kluger N, Jacot W, Frouin E et al (2012) Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. Ann Oncol 23(11):2879–2884. https://doi.org/10.1093/annonc/mds095 (http://www.ncbi.nlm.nih.gov/pubmed/22571858)CrossRefPubMed

44.

Duijnhoven RG, Straus SM, Souverein PC et al (2014) Long-term use of 5alpha-reductase inhibitors and the risk of male breast cancer. Cancer Causes Control 25(11):1577–1582. https://doi.org/10.1007/s10552-014-0455-6CrossRefPubMed

45.

Bird ST, Brophy JM, Hartzema AG, Delaney JA, Etminan M (2013) Male breast cancer and 5alpha-reductase inhibitors finasteride and dutasteride. J Urol 190(5):1811–1814. https://doi.org/10.1016/j.juro.2013.04.132 (http://www.ncbi.nlm.nih.gov/pubmed/23665270)CrossRefPubMed

46.

Meijer M, Thygesen LC, Green A et al (2018) Finasteride treatment and male breast cancer: a register-based cohort study in four nordic countries. Cancer Med 7(1):254–260CrossRefPubMed

47.

Rossi A, Caro G, Magri F, Fortuna MC, Carlesimo M (2021) Clinical aspect, pathogenesis and therapy options of alopecia induced by hormonal therapy for breast cancer. Explor Target Antitumor Ther 2(5):490–495. https://doi.org/10.37349/etat.2021.00059CrossRefPubMedPubMedCentral

48.

Rossi A, Campo D, Fortuna MC, Garelli V, Pranteda G, De Vita G et al (2018) A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia. J Dermatolog Treat 29:149–151. https://doi.org/10.1080/09546634.2017.1341610CrossRefPubMed

49.

Soref CM, Fahl WE (2015) A new strategy to prevent chemotherapy and radiotherapy-induced alopecia using topically applied vasoconstrictor. Int J Cancer 136(1):195–203. https://doi.org/10.1002/ijc.28961CrossRefPubMed

Titel: Hair loss during and after breast cancer therapy
verfasst von: Lucy Rose
Maryam Lustberg
Kathryn J. Ruddy
Elizabeth Cathcart-Rake
Charles Loprinzi
Brittany Dulmage
Publikationsdatum: 01.03.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 3/2023
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-023-07634-5

Sex differences in comorbid conditions, health behaviors, health care utilization, and health-related quality of life among young adult cancer survivors

Research

Association of sexual attitudes with sexual dysfunction and sexual distress among Chinese breast cancer survivors: a cross-sectional study

Research

Communication of costs and financial burdens between cancer patients and healthcare providers: a qualitative systematic review and meta-synthesis

Review

Cost consequences of unscheduled emergency admissions in cancer patients in the last year of life

Open Access
Research

Digital health tools for pain monitoring in pediatric oncology: a scoping review and qualitative assessment of barriers and facilitators of implementation

Open Access
Review

Suicide risk in cancer patients: cancer prognosis and mental health

Correspondence

Neu im Fachgebiet Onkologie

Fortgeschrittenes Melanom: Wann den Checkpoint-Inhibitor absetzen?

20.04.2025
Melanom
Nachrichten

Eine ICI-Therapie sollte bei Betroffenen mit fortgeschrittenem Melanom mindestens ein Jahr fortgesetzt werden. Bei anhaltendem Ansprechen kann danach offenbar ohne hohes Risiko ein Therapieabbruch erwogen werden.

Positive Phase IIb-Studie zu mRNA-gestützter CAR-T bei Myasthenia gravis

17.04.2025
AAN-Jahrestagung 2025
Kongressbericht

Eine auf das B-Zell-Reifungsantigen gerichtete mRNA-basierte CAR-T-Zell-Therapie wurde jetzt in einer ersten Phase IIb-Studie zur Behandlung der generalisierten Myasthenia gravis mit Placebo verglichen.

NSCLC: Hirnmetastasen durch elektrische Felder eindämmen

17.04.2025
DGP 2025
Kongressbericht

Zur Behandlung von Hirnmetasen bei nicht-kleinzelligem Lungenkrebs (NSCLC) stehen verschiedene Optionen zur Verfügung. TTFields – eine lokoregionäre, nicht-invasive physikalische Therapie – könnte sich hier einreihen.

Kontrollkoloskopie nach Polypektomie: Wann ist eine zweite Untersuchung nötig?

17.04.2025
Koloskopie
Nachrichten

Wann benötigen polypektomierte Patienten und Patientinnen mehr als eine endoskopische Nachsorgeuntersuchung? Eine Kohortenstudie aus Großbritannien legt eine konkrete Strategie nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Hair loss during and after breast cancer therapy

Abstract

Weitere Artikel der Ausgabe 3/2023

Sex differences in comorbid conditions, health behaviors, health care utilization, and health-related quality of life among young adult cancer survivors

Association of sexual attitudes with sexual dysfunction and sexual distress among Chinese breast cancer survivors: a cross-sectional study

Communication of costs and financial burdens between cancer patients and healthcare providers: a qualitative systematic review and meta-synthesis

Cost consequences of unscheduled emergency admissions in cancer patients in the last year of life

Digital health tools for pain monitoring in pediatric oncology: a scoping review and qualitative assessment of barriers and facilitators of implementation

Suicide risk in cancer patients: cancer prognosis and mental health

Neu im Fachgebiet Onkologie

Fortgeschrittenes Melanom: Wann den Checkpoint-Inhibitor absetzen?

Positive Phase IIb-Studie zu mRNA-gestützter CAR-T bei Myasthenia gravis

NSCLC: Hirnmetastasen durch elektrische Felder eindämmen

Kontrollkoloskopie nach Polypektomie: Wann ist eine zweite Untersuchung nötig?

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten